Physician profile
Mohammad Khalil
NPI 1669662136
$1,253.76
in general payments reported to CMS, 2019-2025
27 companies · $259 in 2025
The $259 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $24.90 · 2021: $34.70 · 2022: $218 · 2023: $391 · 2024: $327 · 2025: $259.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $960 · Education: $16.72.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $959.62 |
| Education | $16.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $164.04 | 2022-2025 | |
| Celgene Corporation | $158.94 | 2022-2023 | Pomalyst |
| Tempus Ai, INC | $153.79 | 2024-2025 | Xt Cdx |
| Intuitive Surgical, INC. | $92.21 | 2023 | Da Vinci Surgical System |
| Novartis Pharmaceuticals Corporation | $90.39 | 2022-2025 | |
| Eisai INC. | $77.77 | 2023-2024 | |
| E.R. Squibb & Sons, L.L.C. | $59.60 | 2020-2021 | |
| Karyopharm Therapeutics INC. | $45.83 | 2022-2025 | Xpovio |
| Tactile Systems Technology INC | $41.90 | 2022-2023 | Flexitouch Plus, Entre Plus |
| Janssen Biotech, INC. | $36.61 | 2024-2025 | Akeega, Erleada |
| Sobi, INC | $32.52 | 2024 | |
| Genentech USA, INC. | $27.14 | 2025 | Tecentriq |
| Abbvie INC. | $24.43 | 2024 | |
| Cti Biopharma Corp. | $24.23 | 2023 | Vonjo |
| Grifols USA, LLC | $20.89 | 2024 | Prolastin-C Liquid |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Puma Biotechnology, INC. | $19.51 | 2023 | |
| Davol INC. | $19.41 | 2023 | Arista Ah Flexitip |
| Array Biopharma INC | $19.25 | 2025 | Tukysa, Mektovi, Braftovi |
| Genmab U.S., INC. | $18.72 | 2022 | |
| Pharming Healthcare, INC. | $18.17 | 2024 | Ruconest |
| Beigene USA, INC. | $17.86 | 2024 | Brukinsa |
| Morphosys, US INC. | $17.20 | 2022 | |
| Catalyst Pharmaceuticals, INC. | $16.72 | 2024 | |
| Fennec Pharmaceuticals, INC. | $14.83 | 2024 | Pedmark |
| Merck Sharp & Dohme LLC | $14.28 | 2024 | Keytruda, Welireg, Lenvima |
| Novo Nordisk INC | $13.98 | 2023 | Rybelsus, Ozempic |
| Astellas Pharma US INC | $13.54 | 2025 | Vyloy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammad Khalil listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.